keyword
influenza
respiratori
virus
bacteri
pneumonia
innat
immun
interferon
pneumonia
remain
one
lead
caus
death
unit
state
worldwid
influenza
respiratori
viral
infect
often
predispos
individu
sever
clinic
cours
greater
morbid
mortal
bacteri
pneumonia
alon
postvir
bacteri
pneumonia
mediat
complex
interact
virus
normal
nasopharyng
bacteri
flora
host
immun
system
current
manag
strategi
larg
direct
toward
influenza
vaccin
select
appropri
antimicrobi
agent
novel
diagnost
test
therapi
address
complex
pathogenesi
postvir
bacteri
pneumonia
need
mitig
potenti
seriou
complic
particularli
given
ongo
threat
influenza
pandem
bacteri
pneumonia
jason
e
prasso
md
jane
c
deng
md
ms
b
socal
spanish
flu
rage
around
world
burden
morbid
mortal
result
influenza
infect
also
subsequ
bacteri
pneumonia
account
estim
million
death
caus
pandem
influenza
pandem
secondari
bacteri
infect
associ
sever
infect
decreas
attribut
advent
antibiot
coinfect
note
approxim
infect
pandem
particularli
fatal
case
despit
substanti
advanc
medicin
avail
potent
antibacteri
antivir
agent
influenza
pneumonia
remain
among
lead
caus
death
unit
state
worldwid
complex
mechan
underli
pathogenesi
postvir
bacteri
pneumonia
incomplet
understood
involv
varieti
host
microbi
factor
allow
secondari
opportunist
bacteri
infect
aris
viral
infect
individu
articl
review
current
understand
viral
infect
host
suscept
bacteri
pneumonia
well
manag
import
complic
viral
infect
viralbacteri
coinfect
commonli
encount
clinic
problem
although
precis
rate
secondari
bacteri
infect
difficult
quantifi
lack
comprehens
report
system
impract
obtain
microbiolog
test
patient
respiratori
infect
bacteri
pneumonia
estim
complic
influenza
infect
higher
rate
among
hospit
patient
intens
care
unit
fatal
case
influenza
one
mani
viral
pathogen
associ
bacteri
coinfect
human
parainfluenza
viru
adenoviru
human
metapneumoviru
measl
respiratori
syncyti
viru
rsv
human
rhinoviru
coronaviru
also
commonli
associ
secondari
bacteri
pneumonia
virus
influenza
arguabl
import
given
continu
evolv
virul
factor
sheer
number
individu
infect
annual
basi
given
public
health
import
well
fact
influenza
extens
studi
bacteri
pneumonia
follow
influenza
infect
primari
focu
articl
irrespect
offend
viral
organ
causal
agent
secondari
bacteri
pneumonia
larg
reflect
colon
nasopharyng
flora
find
fuel
theori
viral
infect
caus
impair
mucos
ciliari
clearanc
normal
nonpathogen
bacteria
enabl
particular
bacteria
flourish
caus
invas
infect
epidemiolog
streptococcu
pneumonia
staphylococcu
aureu
methicillinsensit
aureu
methicillinresist
aureu
mrsa
common
streptococcu
pyogen
haemophilu
influenza
less
frequent
isol
howev
infect
human
often
polymicrobi
involv
combin
multipl
virus
andor
bacteria
common
viralbacteri
coinfect
summar
tabl
incid
bacteri
pneumonia
mirror
season
natur
viral
infect
increas
peak
viral
season
data
epidem
show
coinfect
usual
occur
within
first
day
influenza
infect
although
develop
day
viral
infect
delay
like
repres
time
need
viral
replic
immunomodulatori
effect
infect
occur
patient
secondari
pneumonia
tend
sever
protract
cours
increas
mortal
compar
without
anteced
viral
infect
although
patient
comorbid
condit
extrem
age
increas
risk
complic
influenza
infect
even
previous
prasso
deng
healthi
patient
develop
sever
respiratori
failur
death
bacteri
pneumonia
follow
influenza
underscor
clinic
signific
problem
secondari
bacteri
pneumonia
one
sever
known
infecti
complic
respiratori
virus
viral
infect
also
associ
acut
otiti
media
bacteri
sinus
children
addit
meningococc
mening
report
complic
influenza
infect
pathogenesi
sever
excel
review
publish
current
mechanist
understand
viral
infect
increas
suscept
secondari
bacteri
pneumonia
thu
articl
provid
brief
overview
primari
focu
viral
mediat
effect
pulmonari
host
defens
subsequ
impair
bacteri
clearanc
tabl
howev
author
acknowledg
microbiolog
epidemiolog
factor
contribut
pathogenesi
viralbacteri
coinfect
colon
nasopharynx
gener
first
step
develop
pneumonia
bacteri
infect
upper
respiratori
tract
includ
sinus
otiti
media
pneumonia
aureu
h
influenza
pyogen
moraxella
catarrhali
normal
inhabit
upper
respiratori
tract
healthi
human
host
lower
respiratori
tract
gener
consid
low
abund
bacteria
although
bacteria
normal
exist
equilibrium
govern
host
intermicrobi
environment
factor
appropri
circumst
prolifer
becom
invas
studi
shown
invers
relationship
nasal
carriag
pneumonia
aureu
group
reveal
antagonist
well
synergist
relationship
member
normal
respiratori
commun
eg
corynebacteria
aureu
corynebacterium
accolen
pneumonia
h
influenza
pneumonia
addit
virus
alter
bacteri
composit
laboratori
recent
examin
chang
nasal
microbiom
follow
intranas
administr
live
attenu
influenza
vaccin
although
individu
host
dispar
microbiom
profil
baselin
vaccin
rel
abund
staphylococc
bacteroid
speci
significantli
increas
find
suggest
viral
stimuli
alter
host
microbiota
potenti
creat
suitabl
environ
otherwis
nonpathogen
organ
grow
becom
invas
disrupt
mucos
barrier
import
potenti
mechan
secondari
bacteri
infect
mucin
present
respiratori
tract
partial
degrad
viral
bacteri
neuraminidas
viral
neuraminidas
tropic
sialic
acid
present
respiratori
epitheli
cell
cleavag
may
uncov
receptor
bacteri
ligand
therebi
promot
bacteri
adhes
infect
furthermor
increas
avail
sialic
acid
airway
shown
promot
growth
prolifer
pneumococcu
use
moieti
nutrient
sourc
murin
model
higher
level
viral
neuraminidas
associ
increas
sever
secondari
bacteri
infect
wherea
treatment
oseltamivir
decreas
bacteri
adher
epitheli
cell
influenza
paramyxovirus
rsv
also
augment
bacteri
adhes
augment
express
receptor
bacteria
epitheli
cell
surfac
one
exampl
plateletactiv
factor
receptor
pafr
bind
phosphorylcholin
present
bacteri
cell
wall
facilit
bacteri
invas
mous
model
pneumococcu
pneumonia
pafr
shown
increas
total
lung
bacteri
load
bacteremia
mortal
howev
block
receptor
show
benefit
influenza
coinfect
model
suggest
mechan
suffici
factor
enhanc
suscept
secondari
bacteri
pneumonia
receptor
involv
adhes
carcinoembryon
antigenrel
cell
adhes
molecul
intracellular
adhes
molecul
overli
express
pulmonari
epitheli
cell
viral
infect
well
epitheli
cell
death
breakdown
tight
junction
result
viral
infect
caus
increas
transloc
bacteria
h
influenza
addit
certain
bacteri
speci
known
bind
affin
basement
membran
extracellular
matrix
protein
suggest
breakdown
epithelium
might
lead
increas
transloc
although
never
prove
critic
mechan
infect
less
cytotox
strain
influenza
vivo
addit
viral
respiratori
infect
known
neg
affect
respiratori
ciliari
function
therebi
impair
host
abil
mechan
clear
aspir
pathogen
lung
macrophag
neutrophil
function
resid
alveolar
macrophag
am
play
integr
role
host
defens
viral
bacteri
pathogen
alik
main
resid
innat
immun
cell
encount
pathogen
rest
lung
engag
phagocytosi
kill
antigen
present
recruit
cell
type
paracrin
endocrin
signal
viral
respiratori
infect
known
impair
macrophag
phagocyt
function
well
monocyt
chemotaxi
lung
earli
influenza
infect
propos
potenti
caus
secondari
bacteri
infect
mous
model
sequenti
influenzabacteri
infect
am
known
decreas
number
increas
suscept
mortal
secondari
bacteri
challeng
influenza
infect
also
shown
downregul
express
class
scaveng
receptor
marco
am
phagocytos
unopson
bacteria
lung
augment
number
function
exogen
granulocytemacrophag
colonystimul
factor
anim
infect
influenza
improv
pneumococcu
clearanc
follow
secondari
bacteri
challeng
increas
reactiv
oxygen
speci
decreas
incid
secondari
pneumonia
viral
infect
affect
abil
am
attract
cell
type
lung
neutrophil
robustli
recruit
follow
elabor
chemokin
am
epitheli
cell
set
invas
bacteri
infect
laboratori
shown
macrophag
express
neutrophil
chemoattract
cxc
motif
chemokin
ligand
kc
cxc
motif
chemokin
ligand
reduc
influenza
infect
consequ
diminish
recruit
neutrophil
lung
desensit
tolllik
receptor
tlr
alveolar
macrophag
may
partial
explain
decreas
neutrophil
recruit
impair
bacteri
clearanc
mice
infect
influenza
rsv
show
decreas
activ
nuclear
factor
kappab
nfkb
express
kc
result
decreas
neutrophil
recruit
lung
stimul
bacteri
ligand
addit
influenza
infect
result
earli
prolong
decreas
pmn
polymorphonuclear
cell
phagocyt
function
depress
reactiv
oxygen
speci
product
thu
viral
infect
multipl
aspect
pulmonari
innat
immun
compromis
lead
impair
antibacteri
host
defens
predominantli
compris
multipl
ifnalpha
protein
ifnbeta
protein
antivir
mediat
secret
multipl
differ
immun
cell
help
limit
viral
replic
induct
type
ifn
known
increas
risk
secondari
bacteri
infect
despit
type
ifn
also
contribut
host
antibacteri
respons
mice
defici
type
ifn
receptor
protect
subsequ
bacteri
challeng
influenza
infect
like
type
ifn
inhibit
kc
product
neutrophil
recruit
lung
monocyt
macrophag
recruit
upper
respiratori
tract
suppress
type
ifn
via
blockad
express
cc
motif
chemokin
ligand
macrophag
chemoattract
result
increas
carriag
pneumonia
studi
highlight
heterogen
effect
ifn
immun
respons
pathogen
viral
respiratori
infect
also
stimul
ifngamma
product
primarili
natur
killer
cell
also
thelper
h
cell
cytotox
cell
neutrophil
context
secondari
bacteri
pneumonia
follow
influenza
ifngamma
shown
impair
phagocytosi
alveolar
macrophag
partial
downregul
scaveng
receptor
marco
inhibit
interleukin
il
result
increas
neutrophil
recruit
lung
improv
clearanc
pneumonia
salvag
anim
death
sequenti
influenzabacteri
infect
howev
normal
host
exogen
administr
result
increas
level
ifngamma
lung
robust
neutrophil
recruit
improv
innat
pulmonari
defens
pneumonia
addit
mous
model
pneumonia
aureu
pneumonia
ifngamma
product
neutrophil
lung
shown
essenti
bacteri
clearanc
possibl
ifngammaregul
product
neutrophil
extracellular
trap
net
paradox
find
naiv
host
versu
host
infect
influenza
suggest
neutrophil
recruit
set
viral
respiratori
infect
unabl
mount
antibacteri
function
would
normal
activ
interferongamma
may
reflect
distinct
neutrophil
phenotyp
set
viral
versu
bacteri
infect
unpublish
data
laboratori
show
strike
transcript
differ
neutrophil
recruit
lung
set
influenza
sequenti
influenza
pneumonia
infect
compar
recruit
set
pneumonia
infect
alon
influenza
infect
known
attenu
h
cellmedi
immun
type
ifn
decreas
product
necessari
polar
h
cell
influenza
aureu
coinfect
result
decreas
monocyt
chemoattract
correl
reduc
clearanc
bacteria
also
like
inhibit
secret
gammadelta
cell
result
increas
suscept
secondari
pneumonia
infect
addit
influenza
infect
mice
shown
suppress
product
antimicrobi
peptid
respons
subsequ
aureu
infect
via
h
mechan
leav
anim
suscept
pneumonia
exogen
administr
antimicrobi
peptid
lipocalin
restor
bacteri
clearanc
anim
differenti
sever
viral
infect
viralbacteri
coinfect
common
diagnost
dilemma
point
present
given
signific
overlap
symptom
laboratori
marker
microbiolog
cultur
result
take
day
wherea
pointofcar
influenza
antigen
test
insuffici
sensit
pcrbase
panel
common
respiratori
viral
pathogen
sensit
use
expens
routin
use
abl
distinguish
colon
versu
true
viral
infect
furthermor
lowvolum
laboratori
result
may
avail
day
radiolog
imag
lobar
consolid
without
pleural
effus
presum
bacteri
howev
multifoc
infiltr
repres
either
multilobar
bacteri
pneumonia
acut
respiratori
distress
syndrom
sever
viral
infect
alon
rsv
adenoviru
hallmark
featur
comput
tomographi
scan
chest
howev
imag
studi
gener
unhelp
increas
creactiv
protein
level
blood
correl
presenc
pneumonia
poorli
distinguish
viral
bacteri
caus
procalcitonin
pct
anoth
serum
biomark
better
abl
differenti
two
one
studi
coinfect
low
pct
level
associ
neg
predict
valu
bacteri
infect
although
patient
shock
malaria
endem
area
may
less
reliabl
thu
given
absenc
rapid
reliabl
diagnost
test
clinician
must
alway
consid
possibl
secondari
bacteri
infect
patient
present
sever
respiratori
infect
influenza
season
manag
accordingli
infect
caus
influenza
measl
h
influenza
pneumonia
strain
adenoviru
consid
vaccineprevent
ill
although
influenza
vaccin
univers
recommend
vaccin
invas
pneumococc
infect
reserv
highrisk
group
includ
children
elderli
patient
immunosuppress
chronic
lung
condit
although
robust
evid
random
placebocontrol
trial
lack
data
anim
model
influenzabacteri
coinfect
observ
studi
patient
indic
influenza
vaccin
reduc
morbid
mortal
associ
bacteri
pneumonia
thu
balanc
vaccin
influenza
current
repres
effect
public
health
strategi
reduc
incid
secondari
bacteri
pneumonia
howev
pneumococc
vaccin
effect
larg
studi
elderli
patient
potenti
replac
cover
serotyp
includ
vaccin
find
mirror
data
anim
model
dual
infect
contrast
vaccin
protein
pyogen
seem
protect
superinfect
unknown
whether
vaccin
pathogen
affect
incid
sever
secondari
bacteri
pneumonia
antibiot
treatment
secondari
bacteri
pneumonia
mirror
local
guidelin
communityacquir
pneumonia
ie
base
local
pattern
antibiot
resist
caveat
patient
increas
risk
aureu
infect
includ
mrsa
patient
cavit
note
imag
sever
respiratori
infect
requir
admiss
intens
care
unit
risk
factor
hospitalacquir
pathogen
treatment
either
vancomycin
linezolid
start
empir
asid
mous
model
influenzamrsa
infect
treatment
linezolid
show
uniqu
immunomodulatori
effect
toxic
product
lung
inflamm
equival
bacteri
clearanc
howev
whether
translat
improv
clinic
outcom
human
still
need
studi
class
antivir
drug
activ
influenza
adamantin
amantadin
rimantadin
neuraminidas
inhibitor
oseltamivir
zanamivir
peramivir
present
use
adamantin
becom
uncommon
high
level
drug
resist
side
effect
previous
mention
viral
infect
often
indistinguish
lower
respiratori
tract
infect
season
heighten
influenza
preval
empir
antivir
therapi
warrant
pend
result
microbiolog
test
ambulatori
patient
symptom
fewer
hour
treatment
oseltamivir
zanamivir
shown
reduc
durat
symptom
hospit
patient
may
benefit
irrespect
symptom
began
given
mechan
action
neuraminidas
inhibitor
theoret
prevent
reduc
sever
secondari
bacteri
pneumonia
effect
describ
anim
model
diseas
pediatr
popul
oseltamivir
use
associ
reduct
subsequ
diagnosi
otiti
media
although
individu
trial
adult
patient
power
detect
effect
oseltamivir
lower
respiratori
tract
infect
metaanalysi
show
decreas
incid
inhal
ribavirin
approv
treatment
sever
rsv
bronchiol
howev
treatment
cumbersom
drug
teratogen
present
problem
hospit
personnel
aerosol
administr
rare
use
effect
secondari
bacteri
infect
unknown
given
role
inflamm
viralbacteri
coinfect
pathogenesi
secondari
pneumonia
signific
interest
util
immunomodulatori
drug
set
corticosteroid
studi
although
data
mous
model
show
protect
secondari
pneumonia
result
delay
viral
clearanc
patient
sever
influenza
infect
result
studi
show
either
benefit
possibl
harm
patient
caus
worsen
infecti
complic
use
recommend
agent
activ
investig
includ
statin
coenzym
reductas
inhibitor
peroxisom
proliferatoractiv
receptor
agonist
cyclooxygenas
inhibitor
macrolid
antibiot
antibodybas
therapi
intraven
immunoglobulin
experiment
monoclon
antibodi
preclin
stage
test
summari
secondari
bacteri
pneumonia
viral
respiratori
infect
remain
signific
sourc
morbid
mortal
suscept
mediat
varieti
viral
bacteri
factor
well
complex
interact
immun
system
infect
host
date
prevent
treatment
strategi
limit
influenza
vaccin
antibioticsantivir
respect
novel
approach
identifi
individu
infect
influenza
increas
risk
secondari
bacteri
pneumonia
urgent
need
given
ongo
threat
anoth
influenza
pandem
given
threat
pandem
heighten
preval
virus
gener
research
immunolog
mechan
diseas
warrant
hope
discov
new
potenti
therapi
